Norwegian screening program reduces breast cancer-related death rates
the ONA take:
A Norwegian breast cancer screening program has markedly reduced breast cancer mortality, according to an evaluation of the pilot project.
As part of the Norwegian Breast Cancer Screening Programme, all women aged 50 to 69 are invited to undergo a mammography screening every 2 years. When the program was launched in 1995, only women in four Norwegian counties were invited to participate, but in 2004, the project went national.
The evaluation showed that the screening program reduced breast cancer mortality by up to 20 to 30% in women aged 50 to 69 who have been followed up until age 79. The goal of the program was to reduce breast cancer-related death by 30%.
The researchers estimate that for every 100,000 women invited to participate in the program, approximately 377 cases of tumors or pre-malignant breast lesions will be identified. Of those, about 27 will avoid breast cancer-related death due to early diagnosis and treatment.
The downside of the program is that approximately 142 per 100,000 women will be overdiagnosed with breast cancer.
A Norwegian breast cancer screening program has markedly reduced breast cancer mortality.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Palliative Cancer Care Should Focus on Symptoms, Not Diagnoses
- COX-2 Inhibitors Can Improve Response to Immunotherapy of Some Cancer Tumors
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|